Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 2/20 | 0.33 |
| ▸ | FURIN | P09958 | 6/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | NPY4R | P50391 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909025 | 0.94 | FAP (0.37) | ELANEFAPFURINCASP1NPY1R | |
| SCHEMBL22267878 | 0.94 | FAP (0.37) | ELANEFAPFURINCASP1NPY1R | |
| SCHEMBL22694922 | 0.94 | FAP (0.37) | ELANEFAPFURINCASP1NPY1R | |
| SCHEMBL18909042 | 0.91 | FAP (0.33) | FAPC3AR1NPY1RNPY4R | |
| SCHEMBL20935177 | 0.90 | NPY5R (0.35) | AKT1POLBC3AR1NPY1RNPY2R | |
| SCHEMBL20935419 | 0.90 | ELANE (0.38) | ELANEFURINC3AR1MAP1LC3B | |
| SCHEMBL20935183 | 0.90 | NPY4R (0.36) | AKT1POLBC3AR1NPY1RNPY2R | |
| SCHEMBL25597931 | 0.89 | C3AR1 (0.41) | FNTAFNTBFAPFURINPOLB | |
| SCHEMBL17722925 | 0.89 | FNTA (0.34) | FNTAFNTBFAPFURINPOLB | |
| SCHEMBL18909027 | 0.89 | FNTA (0.34) | FNTAFNTBFAPFURINPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230037682-A1 | BINDING MOLECULES AGAINST CD3 AND USES THEREOF | NOVARTIS AG (CH) | 2023-02-09 | — | — | US | disclosed |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
| US-11161911-B2 | Anti-glyco-MUC1 antibodies and their uses | GO THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | NOVARTIS AG (CH) | 2021-06-03 | — | — | US | disclosed |
| US-20210139585-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2021-05-13 | — | — | US | disclosed |
| US-20190119400-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | CD44, SIGLEC7, SIGLEC9 | ELANE 4180/4885AKT1 4058/4885FNTA 1339/4885 |
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | ELANE 2919/4885AKT1 2698/4885FNTA 1776/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | ELANE 1821/4885AKT1 1498/4885FNTA 1191/4885 |
| US-20210139585-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | ELANE 4151/4885AKT1 2634/4885FNTA 1585/4885 |
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | CD2, CD4, CD22 | ELANE 3706/4885AKT1 3884/4885FNTA 1598/4885 |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | CD2, CD2BP2, CD22 | ELANE 3553/4885AKT1 3719/4885FNTA 2293/4885 |
| US-20230037682-A1 | BINDING MOLECULES AGAINST CD3 AND USES THEREOF | CD2, CD4, CD14 | ELANE 2785/4885AKT1 4534/4885FNTA 3209/4885 |
| US-11161911-B2 | Anti-glyco-MUC1 antibodies and their uses | MUC1, SIGLEC7, SIGLEC9 | ELANE 3134/4885AKT1 4728/4885FNTA 1045/4885 |
| US-20190119400-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | ELANE 3134/4885AKT1 4728/4885FNTA 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.